**
In a troubling revelation, internal government documents have exposed a meeting between top officials at the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, to discuss ongoing litigation regarding the company’s glyphosate-based herbicides. This meeting, held on 17 June 2025, occurred just months before the Trump administration took significant steps to bolster Bayer’s legal position in the face of numerous cancer-related lawsuits from American consumers.
Corporate Influence on Regulatory Decisions
The EPA meeting, which included key figures such as Lee Zeldin, the agency’s administrator, and various other senior officials, focused on “litigation” strategies, particularly Bayer’s attempts to secure a Supreme Court review of its glyphosate products. This herbicide, widely known through its flagship product Roundup, has been linked to cancer by numerous studies, leading to thousands of lawsuits against Bayer. The core of the legal arguments rests on whether Bayer can be held responsible for failing to warn consumers about these risks, especially if the EPA does not mandate such warnings.
Bayer has claimed that its strategy hinges on the idea that if the EPA does not require cancer warnings, then the company cannot be held liable. While one appellate court sided with Bayer, many others have pushed back against this argument, including the Biden administration’s solicitor general, who voiced opposition to Bayer’s claims. Despite this, the Trump administration has frequently aligned itself with Bayer’s interests, providing a striking contrast to the previous administration’s stance.
The Shadow of Influence
Documents obtained through a Freedom of Information Act request reveal that Bayer’s team was prepared to discuss legal concerns during the June meeting, raising significant questions about the integrity of the regulatory process. Nathan Donley, an environmental health scientist with the Centre for Biological Diversity, articulated these concerns, stating that such high-profile meetings illustrate the overwhelming influence that corporations wield over regulatory bodies.
“When the CEO of one of the largest companies in the world meets with political appointees in a US regulatory office, it demonstrates just how much sway these corporations have on decisions impacting public health,” he commented. The implications of such corporate influence are profound, as they could potentially compromise the safety of American consumers in favour of corporate profitability.
Continuing Support for Bayer
In the wake of this meeting, the Trump administration has taken several actions that appear to favour Bayer. A filing by the U.S. solicitor general in December 2025 urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, scheduling a hearing for April 2026. Furthermore, in February 2026, the White House invoked the Defense Production Act, ensuring the continued production of glyphosate herbicides while simultaneously offering legal protections for companies like Bayer against lawsuits related to cancer claims.
Bayer’s representatives insisted that their interactions with the EPA were merely standard regulatory procedures and claimed that they have been open about their position regarding glyphosate litigation. However, critics argue that these meetings highlight a significant imbalance in the regulatory landscape, where corporate interests seem to overshadow public health concerns.
The Voices of the Affected
Legal experts and advocates have raised alarms over the potential dangers of such close ties between the EPA and corporate entities. Whitney Di Bona, a consumer safety advocate, expressed concern that the meeting agenda prioritised Bayer’s interests while neglecting the voices of thousands of individuals who have suffered from cancer linked to glyphosate exposure.
The discrepancies are stark. While Bayer engages in private discussions with regulatory officials, the thousands of citizens impacted by their products remain largely unheard. Naomi Oreskes, a professor at Harvard, highlighted this disparity, noting a troubling trend where industry leaders have access to government officials that ordinary citizens do not.
Zen Honeycutt, founder of Moms Across America, also voiced her disappointment, stating that such interactions are indicative of a broader pattern of coercion by chemical companies over regulatory agencies. Despite numerous meetings with EPA leadership, advocacy groups often find their calls for action regarding pesticide restrictions largely ignored.
Why it Matters
This unfolding narrative underscores a critical intersection between regulatory integrity and corporate influence in the United States. As the Trump administration continues to demonstrate loyalty to Bayer, the broader implications for public health and safety cannot be ignored. The prioritisation of corporate interests over consumer protection raises urgent questions about accountability and transparency. As citizens grapple with the potential health risks associated with glyphosate, the need for a regulatory framework that prioritises the well-being of the public over profit has never been more pressing. The path forward must involve not only stricter regulations but also a commitment to elevating the voices of those most affected by these powerful corporate entities.
